Common forms: Ubiquinone · Ubiquinol
Used for
CoQ10 isn't tied to one lab marker the way Magnesium or Iron is — it's used here as general mitochondrial support, since it's an essential cofactor for complexes I, II, and III of the electron transport chain, responsible for roughly 95% of cellular ATP production. It's paired with PQQ in this framework as part of the same mitochondrial-support toolkit.
Common forms & typical benefits
What the research says
| Outcome | Approx. evidence base | Typical finding |
|---|---|---|
| Heart failure — cardiovascular events & mortality | Q-SYMBIO RCT, 420 people, 2-year follow-up | Significantly reduced major cardiovascular events and mortality, added to standard therapy |
| Heart failure — broader confirmation | Cochrane review, 11 studies (1,573 people) | Moderate-quality evidence of reduced all-cause mortality and hospitalization |
| Statin-associated muscle symptoms | Meta-analysis, 12 RCTs (575 people) | Significant improvement in muscle pain, weakness, cramping, and tiredness — though other trials in this area have disagreed |
| Blood pressure, dyslipidemia, glycemic control | Various smaller trials | Less impressive, mostly modest or inconsistent effects |
| General energy in non-deficient, healthy people | Limited trial support | No strong evidence of a general energy boost if you aren't actually depleted |
This is one of the stronger evidence profiles in this library, but it's concentrated in specific clinical situations — heart failure and statin-related muscle symptoms — rather than as a general wellness or energy supplement. If someone is healthy with no heart failure or statin-related symptoms, the evidence for a noticeable energy boost is much thinner.
Research summary chart
View PDF ↗Dosages used in studies
| Goal | Typical dose | Notes | Duration |
|---|---|---|---|
| Product used here (Thorne CoQ10/Q-Best 100) | 100–200 mg/day (1-2 gelcaps) | Ubiquinone, proprietary lipid-based formulation | Ongoing, per practitioner |
| Heart failure, research dose (Q-SYMBIO) | 300 mg/day (100 mg 3x/day) | Added to standard heart failure therapy | 2 years |
| Statin-associated muscle symptoms (research range) | 100–300 mg/day | Either form used across trials | 30 days–3 months |
In practice, this is typically given as a single daily dose taken with the morning meal, rather than split across the day the way some higher research doses were.
Safety notes & high-dose risks
Additional notes